Last updated on June 2018

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Neovascular Age-Related Macular Degeneration
  • Age: Between 50 - 100 Years
  • Gender: Male or Female

Key Inclusion Criteria:

  1. Males or females of any race, 50 years of age
  2. Presence of an active CNV lesion secondary to AMD treated with at least 3 monthly injections of an anti-VEGF agent (aflibercept, bevacizumab, or ranibizumab)
  3. Evidence of increased vascular permeability and/or loss of visual acuity

Key Exclusion Criteria:

  1. History, within 6 months prior to screening, of any of the following: myocardial infarction, any cardiac event requiring hospitalization, treatment for acute congestive heart failure, transient ischemic attack, or stroke
  2. Uncontrolled hypertension, diabetes mellitus, IOP, hypothyroidism, or hyperthyroidism
  3. Chronic renal disease
  4. Abnormal liver function
  5. Women who are pregnant or lactating

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.